Radiomics and Image Segmentation of Urinary Stones by Artificial Intelligence
Launched by OSLO UNIVERSITY HOSPITAL · May 8, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring how well artificial intelligence (AI) can help doctors analyze CT scans of patients with kidney stones. Kidney stones can cause severe pain and other serious health issues, especially if they block the ureters, which are the tubes that carry urine from the kidneys to the bladder. The study aims to see if using AI to process these images can provide more accurate information about kidney stones compared to the traditional methods done by doctors. This could help in better diagnosing the condition and deciding the best treatment options.
To participate in the trial, individuals must be at least 18 years old and should have been referred for a CT scan due to a suspected kidney stone problem, either from recent pain or a known history of kidney stones. Unfortunately, those who are not experiencing symptoms or are undergoing routine scans after treatment will not be eligible. Participants in the study can expect to have their CT scans analyzed using both traditional methods and AI, helping researchers understand which method provides the best insights into kidney stone disease. This trial is not yet recruiting participants, but it represents an important step towards improving kidney stone diagnosis and treatment.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Referral for CT due to episode of renal colic and clinical suspicion of urinary stone disease or
- • Referral for CT due to new episode of pain in patient with known urinary stone disease
- • Age ≥ 18 years
- Exclusion Criteria:
- • Referral for control CT of asymptomatic patients with known urinary stone disease
- • Referral for control CT after treatment
- • Referral for control CT for spontaneous passage of stone.
- • Lack of informed consent for any reason.
About Oslo University Hospital
Oslo University Hospital is a leading academic medical center in Norway, renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, the hospital integrates cutting-edge scientific inquiry with patient care, fostering an environment that promotes the development of new therapies and treatment strategies. With a multidisciplinary approach, Oslo University Hospital collaborates with various stakeholders, including researchers, healthcare professionals, and industry partners, to enhance clinical outcomes and contribute to the global medical community. Its dedication to ethical standards and patient safety ensures that all trials are conducted with the highest level of integrity and respect for participant welfare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Peter M. Lauritzen, MD, PhD
Principal Investigator
Oslo University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported